Oppenheimer Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $46.00
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target upped by Oppenheimer from $40.00 to $46.00 in a report released on Monday morning, Marketbeat reports. The firm currently has an outperform rating on the stock. Other research analysts also recently issued reports about the company. HC Wainwright reissued a buy rating and issued a […]